Domvanalimab (AB154) is an anti-TIGIT humanized monoclonal antibody. Domvanalimab binds human TIGIT9 and blocks the TIGIT-CD155 interaction. Domvanalimab can be used in research of cancer.
References:
[1]. Dolgin E. Antibody engineers seek optimal drug targeting TIGIT checkpoint. Nat Biotechnol. 2020 Sep;38(9):1007-1009.
















